Skip to content
Press
  • 3 Mar 2026

    Citywire: HgCapital proves its business as usual after tech rout

  • 2 Mar 2026

    AJ Bell Money & Markets: Investment Trust Show: How fund managers handle “sin stocks”

  • 19 Feb 2026

    Citywire: RTW: We’re in the early innings of a biotech recovery

  • 6 Feb 2026

    Citywire: HgCapital rallies as it reassures investors and launches buybacks

  • 26 Jan 2026

    Portfolio Adviser: RTW Biotech’s Wong: GLP-1s are tackling the ‘largest pharmaceutical event the industry has ever seen’

  • 26 Jan 2026

    Financial Times: China’s labs pull ahead as global drugmakers invest in biotech pioneers

  • 20 Jan 2026

    Interactive investor: Funds and trusts four pros are buying and selling: Q1 2026

Investor Portal

Exclusive access for professional investors

The Investor Portal provides professional investors with exclusive access to upcoming Cadarn events, detailed fund portfolio insights and associated fund materials. A dedicated information hub that offers an insight into our fund partners’ respective investment approaches, market insights and fund news.

Sign up

Cadarn Capital Ltd (FRN: 998015) is an appointed representative of Thornbridge Investment Management LLP (FRN: 713859) which is authorised and regulated by the Financial Conduct Authority